STOCK TITAN

SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
SI-BONE, Inc. will be participating in the Jefferies London Healthcare Conference on November 15, 2023. The company will host a fireside chat at 4:00 a.m. ET / 1:00 a.m. PT. Investors can register to listen to the conference call via a provided link. The webcast will be available on the company's website and archived for at least 90 days.
Positive
  • None.
Negative
  • None.

SANTA CLARA, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Jefferies London Healthcare Conference in London, UK. Management will be hosting a fireside chat on Wednesday, November 15, 2023, at 4:00 a.m. Eastern Time / 1:00 a.m. Pacific Time.

Investors interested in listening to the conference call may do so by registering at this link: https://wsw.com/webcast/jeff287/sibn/1855312. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,000 surgeons in performing a total of over 85,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 120 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE, iFuse Implant System and iFuse-TORQ are registered trademarks of SI-BONE, Inc. ©2023 SI-BONE, Inc. All Rights Reserved.

Investor Contact:
Saqib Iqbal
Sr. Director, FP&A and Investor Relations
investors@SI-BONE.com

 


FAQ

What is the name of the company participating in the Jefferies London Healthcare Conference?

The company participating in the conference is SI-BONE, Inc.

When will the fireside chat hosted by SI-BONE, Inc. take place?

The fireside chat will take place on Wednesday, November 15, 2023.

Where can investors register to listen to the conference call?

Investors can register to listen to the conference call at the provided link: https://wsw.com/webcast/jeff287/sibn/1855312.

Where will the webcast be available?

The webcast will be available on the 'Investors' section of SI-BONE, Inc.'s website at: www.si-bone.com.

How long will the webcast be available for replay?

The webcast will be archived and available for replay for at least 90 days after the event.

SI-BONE, Inc.

NASDAQ:SIBN

SIBN Rankings

SIBN Latest News

SIBN Stock Data

558.32M
37.81M
2.38%
98.43%
5.95%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SANTA CLARA

About SIBN

si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al